2012 Case #6 |
Diagnosis: Chromoblastomycosis due to Phialophora verrucosa. |
Discussion: Microscopic examination of a skin biopsy disclosed pigmented thick walled multi-celled structures called sclerotic bodies or muriform bodies [Image C]. Sclerotic bodies can usually also been seen on a simple KOH preparation from a scraping of one of the black dots. Culture of the scrapings on Saborauds agar grew Phialophora verrucosa with characteristic flask-shaped or elliptical phialides with a distinctive funnel-shape. PCR confirmation is pending [Image D].
Subcutaneous mycoses are a heterogeneous group of diseases and organisms that share the characteristic that they develop at the site of skin penetrating trauma. Etiologic agents of subcutaneous mycoses are divided into several groups:
Chromoblastomycosis occurs worldwide, including in the USA, but 70% of cases are estimated to occur in the moist tropics. Most cases in Latin America are from the humid Amazon of Brazil, from Mexico, and from Costa Rica, but cases are reported from Colombia, Ecuador, Venezuela, Argentina, the Dominican Republic, and Cuba. Many cases are reported from Madagascar and South Africa. Up to 90% of cases occur in males likely due to occupational factors. The differential diagnosis in our patient includes: sporotrichosis [Gorgas Case 2008-01], eumycetoma [Gorgas Case 2002-04], lobomycosis (lacaziosis) [Gorgas Case 2005-03], subcutaneous zygomycosis, subcutaneous phaeohyphomycosis, botryomycosis [Gorgas Case 2003-04], leishmaniasis [Gorgas Case 2004-01], nocardiosis [Gorgas Case 2011-01], cutaneous tuberculosis, leprosy, and benign and malignant tumors (e.g., Kaposi’s and other sarcomas). Treatment of chromoblastomycosis is based on case report and case series; there are no controlled trials. Treatment choices include itraconazole alone or in combination with flucytsosine, terbinafine, cryosurgery, or heat. Small lesions may respond to surgery, heat, or cryotherapy alone [Curr Opin Infect Dis. 2009 Dec;22(6):559-63]. Our patient is receiving 200 mg/day of itraconazole and has had 2 cryotherapy applications so far. Image E shows his lesion after 4 weeks of itraconazole. Of the newer azoles voriconazole has potent in vitro activity against Cladiphialophora carrionii, F. pedrosoi, and Phialophora verrucosa; posaconazole is approved in Europe for refractory chromoblastomycosis; and caspofungin has potent in vitro activity against F. pedrosoi [Med Mycol. 2011 Apr;49(3):225-36]. Acknowledgements: We thank Dr. Francisco Bravo, Gorgas Dermatology Professor and Dr. Betty Bustamante, Director of the IMT Mycology Lab. |